Compare TEVA & CLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | CLS |
|---|---|---|
| Founded | 1901 | 1994 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 32.5B |
| IPO Year | N/A | 1998 |
| Metric | TEVA | CLS |
|---|---|---|
| Price | $30.30 | $310.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $29.78 | ★ $308.77 |
| AVG Volume (30 Days) | ★ 10.6M | 3.1M |
| Earning Date | 01-28-2026 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.66 |
| EPS | 0.62 | ★ 6.15 |
| Revenue | ★ $16,776,000,000.00 | $11,281,700,000.00 |
| Revenue This Year | $4.74 | $27.66 |
| Revenue Next Year | $0.48 | $32.94 |
| P/E Ratio | ★ $48.27 | $49.82 |
| Revenue Growth | 0.02 | ★ 22.09 |
| 52 Week Low | $12.47 | $58.05 |
| 52 Week High | $30.20 | $363.40 |
| Indicator | TEVA | CLS |
|---|---|---|
| Relative Strength Index (RSI) | 81.00 | 47.14 |
| Support Level | $28.00 | $297.35 |
| Resistance Level | $30.20 | $353.38 |
| Average True Range (ATR) | 0.66 | 18.97 |
| MACD | 0.16 | -1.72 |
| Stochastic Oscillator | 96.20 | 21.85 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, The Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.